ViroCell

ViroCell Biologics manufactures viral vectors and gene-modified cells to enable novel cell and gene therapies (CGTs) to enter clinical trials.

ViroCell Biologics manufactures viral vectors and gene-modified cells to enable novel cell and gene therapies (CGTs) to enter clinical trials.

Leveraging the team’s 20-year track record of manufacturing more than 100 unique vectors, ViroCell is helping to accelerate the development of crucial, cutting edge therapies so that disease can recede and progress can prevail.

ViroCell is working in partnership with the Royal Free Hospital and Great Ormond Street Hospital.

Website: www.virocell.com

News from Disruptive capital GP Limited